Scinopharm Taiwan (TPE:1789) FCF Margin % : 19.93% (As of Dec. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Scinopharm Taiwan FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Scinopharm Taiwan's Free Cash Flow for the three months ended in Dec. 2024 was NT$207 Mil. Scinopharm Taiwan's Revenue for the three months ended in Dec. 2024 was NT$1,036 Mil. Therefore, Scinopharm Taiwan's FCF Margin % for the quarter that ended in Dec. 2024 was 19.93%.

As of today, Scinopharm Taiwan's current FCF Yield % is 3.52%.

The historical rank and industry rank for Scinopharm Taiwan's FCF Margin % or its related term are showing as below:

TPE:1789' s FCF Margin % Range Over the Past 10 Years
Min: -1.68 Med: 16 Max: 31.34
Current: 13.57

During the past 13 years, the highest FCF Margin % of Scinopharm Taiwan was 31.34%. The lowest was -1.68%. And the median was 16.00%.

TPE:1789's FCF Margin % is ranked better than
81.08% of 978 companies
in the Drug Manufacturers industry
Industry Median: 0.87 vs TPE:1789: 13.57

Scinopharm Taiwan FCF Margin % Historical Data

The historical data trend for Scinopharm Taiwan's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scinopharm Taiwan FCF Margin % Chart

Scinopharm Taiwan Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

24.76

6.82

16.05

-1.68

13.57

Scinopharm Taiwan Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-1.56	33.14	-0.91	-4.15	19.93

Competitive Comparison of Scinopharm Taiwan's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Scinopharm Taiwan's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scinopharm Taiwan's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Scinopharm Taiwan's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Scinopharm Taiwan's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Scinopharm Taiwan FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Scinopharm Taiwan's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	462.181	/	3406.284
	=	13.57 %

Scinopharm Taiwan's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	206.545	/	1036.476
	=	19.93 %

Scinopharm Taiwan FCF Margin % Related Terms

Thank you for viewing the detailed overview of Scinopharm Taiwan's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Scinopharm Taiwan Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Scinopharm Taiwan Ltd (TPE:1789) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1, Nan-Ke 8th Road, Southern Taiwan Science Park, Shan-Hua, Tainan, TWN, 74144

Website

https://www.scinopharm.com

Scinopharm Taiwan Ltd is a specialty and generic drug manufacturing company. The company is primarily engaged in the manufacturing of medicines, chemicals, biological technology services, active pharmaceutical ingredients, albumin medicines, injections, and new small molecule drugs. Schinopharm also conducts consulting and technical services. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. The Company's sales revenue mainly arises from the manufacture and sales of Active Pharmaceutical Ingredient and injection products.

Scinopharm Taiwan Headlines

No Headlines